Wild-type p53 gene-induced morphological changes and growth suppression in hepatoma cells

Journal of Gastroenterology

Volumn 32, Issue 3, 1997, Pages 330-337

  Terai, Shuji ^a   Noma, Takafumi ^a   Kimura, Teruaki ^a   Nakazawa, Atsushi ^a   Kurokawa, Fumie ^a   Okita, Kiwamu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dominant negative effect; Hepatocellular carcinoma; p53; Phenotypical changes; Transcriptional activation

Indexed keywords

ALANINE; COMPLEMENTARY DNA; GLYCINE; LIPOSOME; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; FETAL CALF SERUM; GENE MUTATION; GENETIC TRANSFECTION; GROWTH INHIBITION; GROWTH RATE; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030968264     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02934489     Document Type: Article

References (57)

1. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutation in human cancers. Science 1991;253:49-53.
2. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342: 705-708.
3. Baker SJ, Preisinger AC, Jessup, JM, et al. p53 gene mutations occur in combination with 17p allelic deletion as late events in colorectal tumorigenesis. Cancer Res 1989;50:7717-7722.
4. Mietz JA, Unger T, Huibregtse JM, et al. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1989; 11:5013-5020.
5. Truant M, Antunovic J, Greenblatt J, et al. Direct interaction of the hepatitis B virus HBX protein with p53 leads to inhibition by HBX of p53 response element-directed transactivation. J Virol 1995;69:1851-1859.
6. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
7. Moll UM, LaQuaglia M, Bénard J, et al. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995;92:4407-4411.
8. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986;6:1379-1385.
9. Unger T, Nau MM, Segal S, et al. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 1992;11:1383-1390.
10. Pavletich NP, Chambers KA, Pabo CO, et al. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 1993;7:2556-2564.
11. Wang Y, Reed M, Wang P, et al. p53 domains: Identification and characterization of two autonomous DNA-binding regions. Genes Dev 1993;7:2575-2586.
12. Bargonetti J, Manfredi JJ, Chen X, et al. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 1993;7:2565-2574.
13. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993;7:855-865.
14. Pietenpol JA, Tokino T, Thiagalingam S, et al. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 1994;91:1998-2002.
15. El-Deiry WS, Kern SE, Pietenpol JA, et al. Definition of a consensus binding site for p53. Nature Genet 1992;1:45-49.
16. Juvan T, Barak Y, Zauberman A, et al. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within mdm2 gene. Oncogene 1993;8:3411-3416.
17. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia. Cell 1992;71:587-597.
18. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
19. Ginsberg D, Mechta F, Yaniv M, et al. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 1991;88:9979-9983.
20. Goyette MC, Cho K, Fasching CL, et al. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992;12:1387-1395.
21. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249:912-915.
22. Chen P-L, Chen Y, Bookstein R, et al. Genetic mechanism of tumor suppresssion by the human p53 gene. Science 1990;250: 1576-1580.
23. Diller L, Kassel J, Nelson CE, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10:5772-5781.
24. Casey G, Lo-Hsueh M, Lopez ME, et al. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991;6:1791-1797.
25. Yonish-Rouach K, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-347.
26. Takahashi T, Garbone D, Takahashi T, et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992;52:2340-2343.
27. Yin Y, Tainsky MA, Bischoff FZ, et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-948.
28. Fujiwara T, Grimm EA, Mukhopadyay T, et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993;53:4129-4133.
29. Dumenco L, Oguey D, Wu J, et al. Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology 1995;22:1279-1288.
30. Mimer J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991;65:765-774.
31. Kern SE, Pietenpol JA, Thiagalingam S, et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256: 827-830.
32. Doi I, Namba M, Sato J, et al. Establishment and some biological characteristics of human hepatoma cell lines. Gann 1975;66:385-392.
33. Hsu IC, Tokiwa T, Bennett W, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993;14:987-992.
34. Farshid M, Tabor E. Expression of oncogenes and tumor suppressor genes in human hepatocellular carcinoma and hepatoblastoma cell lines. J Med Virol 1992;38:235-239.
35. Terai S, Matsuzaki Y, Masuhara M, et al. High MDM2 mRNA expression in hepatoblastoma cell lines. Int Hepatol Commun 1995;3:330-336.
36. Nishida N, Fukuda Y, Kokuryu H, et al. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 1993;53:368-372.
37. Levine AJ, Momand J, Finlay CA, et al. The p53 tumor suppressor gene. Nature 1991;351:453-456.
38. Aden DP, Fogel A, Plotkin S, et al. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979;282:615-616.
39. Felgner PL, Gadek TR, Holm M, et al. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7417.
40. Harlow E, Williamson NM, Ralston R, et al. Molecular cloning and in vitro expression of a cDN A clone for human cellular tumor antigen p53. Mol Cell Biol 1985;5:1601-1610.
41. Vistica DT, Skehan P, Scudiero D, et al. Tetrazolium-based assays for cellular viability: A critical examination of selected parameters affecting formazan production. Cancer Res 1991;51:2515-2520.
42. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
43. Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-534.
44. MacGregor GR, Caskey CT. Construction of plasmids that express E.coli β-galactosidase in mammalian cells. Nucleic Acids Res 1989;17:2365.
45. Neumann JR, Morency CA, Russian KO, et al. A novel rapid assay for chloramphenicol acetyltransferase gene expression. Res Rep Health Eff Inst 1987;5:444-447.
46. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degradated proteins: The PEST hypothesis. Science 1986;234:364-368.
47. Bhatia K, Goldschmidts W, Gutierrez M, et al. Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEB J 1993;7: 951-956.
48. Rogel B, Poplinker M, Webb CG, et al. p53 cellular tumor antigen: Analysis of mRNA level in normal adult tissue, embryos, and tumors. Mol Cell Biol 1985;5:2851-2855.
49. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990;62:671-680.
50. Shaulsky G, Goldfinger N, Ben-Ze'ev A, et al. Nuclear accumulation of p53 protein is mediated by several nucelar localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990;10: 6565-6577.
51. Shaulsky G, Ben-Ze'ev A, Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c3T3 cells. Oncogene 1990;5:1707-1711.
52. Gannon JV, Lane DP. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature 1991;349:802-806.
53. Takahashi K, Sumimoto H, Suzuki K, et al. Protein synthesis-dependent cytoplasmic translocation of p53 protein after serum stimulation of growth-arrested MCF-7 cells. Mol Carcinog 1993; 8:58-66.
54. Takahashi K, Suzuki K. Association of insulin-like growth-factor-1 induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int J Cancer 1993;55:453-458.
55. Suzuki K, Ono T, Takahashi K. Inhibition of DNA synthesis by TGF-β1 coincides with inhibition of phosphorylation and cytoplasmic translocation of p53 protein. Biochem Biophys Res Commun 1992;183:1175-1183.
56. Mogi Y, Kato J, Horimoto M, et al. Close correlation between the dephosphorylation of p53 and growth suppression by transforming growth factor-β1 in nasopharyngeal carcinoma cells transduced with adenovirus early region genes. Jpn J Cancer Res 1994;85:459-463.
57. Hupp TR, Meek DW, Midgley CA, et al. Regulation of the specific DNA binding function of p53. Cell 1992;71;875-886.